Loss to Follow-Up Among Patients With Proliferative Diabetic Retinopathy in Clinical Practice

Suresh, Rishi; Yu, Hannah J.; Thoveson, Alec; Swisher, Jeremy; Apolinario, Michael; Zhou, Brenda; Shah, Ankoor; Fish, Richard H.; Wykoff, Charles C.

doi:10.1016/j.ajo.2020.03.011

Cited by 36 publications

(41 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6,[9][10][11]21 In a study of patients with PDR, having a lower income had higher odds of being lost to followup. 10,22 The effects of these features on follow-up adherence in this study were small but significant in the univariate analysis, however dropped out in multivariate analysis. Still, these findings collectively suggest the presence of systemic factors as barriers to appointment adherence in diabetic eye care.…”

Section: Diabetic Retinopathy May Lead To Vision-threatening Conseque...mentioning

confidence: 56%

Follow-Up Adherence in Patients With Nonproliferative Diabetic Retinopathy Presenting to an Ophthalmic Emergency Department

Watane¹,

Kalavar²,

Vanner³

et al. 2021

Retina

View full text Add to dashboard Cite

To determine the rate of follow-up after emergent encounters for nonproliferative diabetic retinopathy and to identify patient or visit characteristics associated with follow-up adherence.Methods: A retrospective cohort study of patients presenting to an ophthalmic emergency department with nonproliferative diabetic retinopathy between May 2014 and December 2018 was conducted. Demographic and encounter data were gathered. Adherence to follow-up was defined as a completed encounter within 5 weeks of the recommended follow-up.Results: A total of 1,248 patients were included. The overall follow-up rate was 53%. Significantly decreased odds of follow-up adherence were associated with longer physician recommended follow-up intervals (odds ratio: 0.81, P , 0.001), longer interval to scheduled appointment (OR: 0.98, P , 0.001), commercial insurance (OR: 0.76, P = 0.01), and lack of any insurance (OR: 0.57, P , 0.01). Significantly increased odds were associated with a longer emergency department visit duration (OR: 1.002, P = 0.001), farther home distance (1.02, P , 0.01), increased likelihood of living in a higher income area (OR: 1.07, P = 0.04),

show abstract

Section: Diabetic Retinopathy May Lead To Vision-threatening Conseque...mentioning

confidence: 56%

Follow-Up Adherence in Patients With Nonproliferative Diabetic Retinopathy Presenting to an Ophthalmic Emergency Department

Watane¹,

Kalavar²,

Vanner³

et al. 2021

Retina

View full text Add to dashboard Cite

show abstract

“…Additionally, there was a notably high rate of LTFU in the current study, with only 29 of 40 enrolled subjects entering year 2, and 25 subjects completing the week 104 endpoint. LTFU is a well-known challenge among patients with DR, as noted in year 1 of the PRIME trial [ 14 ] and in multiple other studies [ 29 , 30 ], despite the need for close clinical follow-up among this population. In the current trial, some cases of LTFU may have been due to the length of trial visits and the need for UWFA, FP, and multiple other images at each study visit.…”

Section: Discussionmentioning

confidence: 99%

Real-Time Diabetic Retinopathy Severity Score Level versus Ultra-Widefield Leakage Index-Guided Management of Diabetic Retinopathy: Two-Year Outcomes from the Randomized PRIME Trial

Ehlers

Sevgi

et al. 2021

JPM

Self Cite

View full text Add to dashboard Cite

The prospective PRIME trial applied real-time, objective imaging biomarkers to determine individualized retreatment needs with intravitreal aflibercept injections (IAI) among eyes with diabetic retinopathy (DR). 40 eyes with nonproliferative or proliferative DR without diabetic macular edema received monthly IAI until a DR severity scale (DRSS) level improvement of ≥2 steps was achieved. Eyes were randomized 1:1 to DRSS- or PLI- guided management. At the final 2-year visit, DRSS level was stable or improved compared to baseline in all eyes, and mean PLI decreased by 11% (p = 0.73) and 23.6% (p = 0.25) in the DRSS- and PLI-guided arms. In both arms, the percent of pro re nata (PRN) visits requiring IAI was significantly higher in year 2 versus 1 (p < 0.0001). The percent of PRN visits receiving IAI during year 1 was significantly correlated with the percent of PRN visits with IAI during year 2 (p < 0.0001). Through week 104, 77.4% of instances of DRSS level worsening in the DRSS-guided arm were preceded by or occurred alongside an increase of PLI. Overall, consistent IAI re-treatment interval requirements were observed longitudinally among individual patients. Additionally, PLI increases appeared to precede DRSS level worsening, highlighting PLI as a valuable biomarker in the management of DR.

show abstract

“…Diabetic retinopathy (DR), a serious complication of diabetes mellitus (DM) caused by microvascular ischemia and hypoxemia, affects approximately 35% of DM patients and an estimated more than 90 million people worldwide [1,2]. The prevalence of proliferative diabetic retinopathy (PDR), a visionthreatening type of DR characterized by retinal neovascular and even vitreous hemorrhage (VH), is nearly 7% [3].…”

Section: Introductionmentioning

confidence: 99%

Network Pharmacology-based Approach to Comparatively Predict the Active Ingredients and Molecular Targets of Compound Xueshuantong Capsule and Hexuemingmu Tablet in the Treatment of Proliferative Diabetic Retinopathy

Yao

Xin

Zhan

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Compound Xueshuantong capsule (CXC) and Hexuemingmu tablet (HXMMT) are two important Chinese patent medicines (CPMs) frequently used to treat proliferative diabetic retinopathy (PDR), especially when complicated with vitreous hemorrhage (VH). However, a network pharmacology approach to understand the therapeutic mechanisms of these two CPMs in PDR has not been applied. The aim of the study was to identify differences in active ingredients between CXC and HXMMT and to comparatively predict and further analyze the molecular targets shared by these CPMs and PDR. Materials and methods The differentially expressed messenger RNAs (mRNAs) between normal retinal tissues in healthy individuals and active fibrovascular membranes in PDR patients were retrieved from the Gene Expression Omnibus database. The active ingredients of CXC and HXMMT and the targets of these ingredients were retrieved from the Traditional Chinese Medicine Systems Pharmacology database. The intersections of the CPM (CXC and HXMMT) targets and PDR targets were determined. Then, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed, and the ingredient-target networks, protein-protein interaction networks and KEGG-target (KEGG-T) networks were constructed. Results There CXC contains 4 herbal drugs in CXC, and HXMMT contains 19. Radix salviae is the only herbal drug common to both. CXC had 34 potential therapeutic targets in PDR, while HXMMT had these 34 and 10 additional targets. Both CPMs shared the following main processes: response to reactive oxygen species and oxidative stress, regulation of blood vessel diameter and size, vasoconstriction, smooth muscle contraction, hemostasis and blood coagulation. The shared pathways included the AGE-RAGE signaling pathway in diabetic complications, TNF signaling pathway, relaxin signaling pathway, IL-17 signaling pathway, etc. Conclusions Both CXC and HXMMT include components effective in treating PDR. Radix salviae, the only herbal drug common to both CPMs, contains many useful active ingredients. HXMMT has more therapeutic targets shared by different active ingredients and more abundant gene functions than CXC. Moreover, the AGE-RAGE signaling pathway in diabetic complications was the most significantly enriched pathway in both networks. However, these findings should be verified through further research.

show abstract

Loss to Follow-Up Among Patients With Proliferative Diabetic Retinopathy in Clinical Practice

Cited by 36 publications

References 15 publications

Follow-Up Adherence in Patients With Nonproliferative Diabetic Retinopathy Presenting to an Ophthalmic Emergency Department

Follow-Up Adherence in Patients With Nonproliferative Diabetic Retinopathy Presenting to an Ophthalmic Emergency Department

Real-Time Diabetic Retinopathy Severity Score Level versus Ultra-Widefield Leakage Index-Guided Management of Diabetic Retinopathy: Two-Year Outcomes from the Randomized PRIME Trial

Network Pharmacology-based Approach to Comparatively Predict the Active Ingredients and Molecular Targets of Compound Xueshuantong Capsule and Hexuemingmu Tablet in the Treatment of Proliferative Diabetic Retinopathy

Contact Info

Product

Resources

About